I'm sure it would be interesting to read, but like most things hindsight is 20/20. My guess is even those experienced with these FDA discussions look back where efficiencies could have occurred given similar situations as ours with combo, mono and other indiciations coming into the fold.

I agree that NP has likely learned a lot of this over the years too, but I would think that our CRO, Amarex, plays a role in these meetings and discussions and not solely NP. I'm not giving him or anyone a pass if mistakes were made, just pointing out that we have a CRO for these specific reasons as CytoDyn (or most small pre-revenue biotech) doesn't have the number of employees or internal experience to navigate everything.